A commentary by researchers from Mayo Clinic and the University of Southern California suggests that agencies funding biomedical research must strive for diversity, equity and inclusion in research decisions, and that these agencies will only be successful if they address bias in the research funding p...
JCSU editors reject many papers without peer review for a few common reasons. To help you decide whether JCSU is right for your manuscript, and to prepare your submission, please be aware that we check papers against the . . .
In this Review, we deliberate on how to improve and expand the antigen repertoire for vaccines, consider developments in vaccine platforms and explore antigen-agnostic in situ vaccines. Furthermore, we summarize the reasons for failure of cancer vaccines in the past and provide an overview of ...
Over 50 years of cancer research has resulted in the generation of massive amounts of information, but relatively little progress has been made in the treatment of patients with solid tumors, except for extending their survival for a few months at best. Here, we will briefly discuss some of ...
Reasons for the poor prognosis of BCYW are likely multifactorial and may be partially explained by the unique tumour biology in younger patients. Younger women are more likely to have tumours of higher grade, larger size, ER/PR negative, and lymph-node positive (p < 0.001) [204,205]. Mult...
I have done extensive research on the internet but it wasn’t until I discovered the book “The Great Prostate Hoax” written by Richard J Ablin, PhD , the doctor who discovered PSA that I realised just how seriously flawed the medical treatments for Prostate cancer really are and how the...
Over the years dealing with cancer patients, I come to realize that to know the truthyou need to see and search for truth yourself. Don’t expect everything to be served on a silver platter for you. Don’t have the misconception that the final decision you made (based on what you “...
Detecting cancer early is essential to improving cancer outcomes. Minoritized groups remain underrepresented in early detection cancer research, which means that findings and interventions are not generalisable across the population, thus exacerbating di
"The early-stage clinical activity of INCB123667 represents an exciting and promising breakthrough for patients with ovarian cancer," said Pablo Cagnoni M.D., President, Head of Research and Development, Incyte. "We believe this novel CDK2 inhibitor has the potential to...
Because for years, NCI only spent 4% of their research budget on childhood cancers, advocates complained to the NCI with shouts of, “More Than 4!” Today it’s about 8% and that’s progress, but most advocates will continue to say it’s still not enough. Will we hear shouts of “...